Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the long-term heart health of women who have experienced peripartum cardiomyopathy (PPCM), a type of heart condition that can develop during late pregnancy or shortly after giving birth. The study aims to find out the best timing for stopping medication for these patients after their heart function has improved. About half of the women diagnosed with PPCM recover their heart function within six months, while others may take longer or experience ongoing heart issues. However, there is uncertainty about when it is safe to stop medication, which this trial seeks to clarify.

To participate in the study, women aged 20 to 45 who have been diagnosed with PPCM and are currently receiving treatment may be eligible. They should have specific heart function measurements that indicate the condition. Participants can expect to contribute to important research that could help guide future treatment decisions for PPCM, potentially improving care for many women. This trial is not yet recruiting participants, so those interested will need to wait for further announcements.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Perinatal cardiomyopathy patients aged 20-45 years who meet the diagnostic criteria for perinatal cardiomyopathy, i.e.: heart failure and left ventricular systolic hypoplasia occurring in the last trimester of gestation or 5 months postpartum; no previous history of heart failure and other etiologies that could explain the heart failure; impaired left ventricular function as indicated by cardiac ultrasound: LVEF \<45% and/or FS \<30% or left ventricular end-diastolic internal diameter ( LVEDd) \> 5.0 cm; (ii) Those who have been diagnosed with perinatal cardiomyopathy and are now receiving standardized drug therapy, and whose cardiac function has not yet recovered, and whose enrollment time is not more than 1 year from the time of diagnosis.
• Exclusion Criteria:
• • (i) Those with a previous history of severe organic valvular disease; (ii) Those with a previous history of diabetes mellitus, chronic hypertension and thyroid disease;
• • Those with history of congenital heart disease, ischemic cardiomyopathy and other cardiomyopathies; ④ Those with severe infections and impaired liver and kidney functions (eGFR \<30ml/min/1.73m2, or transaminases more than 5 times higher than the upper limit of normal values); ⑤ Those with previous persistent atrial, supraventricular or ventricular arrhythmia and have to be treated with anti-arrhythmic drugs for a long time; (vi) Those with serious adverse reactions and contraindications to heart failure therapeutic drugs.